Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases

References

• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011; 12:509–17; PMID:21739679; http://dx.doi.org/10.1038/ni.2039
   PubMed Web of Science ®Google Scholar
• Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009; 98:1278-316; PMID:18704954; http://dx.doi.org/10.1002/jps.21523
   PubMed Web of Science ®Google Scholar
• CDC. Immunization Schedules for Children in Easy-to-read Formats. CDC: Atlanta, GA; 2014. Available from http://www.cdc.gov/vaccines/schedules/easy-to-read/child.html
   Google Scholar
• Maina LC, Karanja S, Kombich J. Immunization coverage and its determinants among children aged 12 - 23 months in a peri-urban area of Kenya. Pan Afr Med J 2013; 14:3; PMID:23504493; http://dx.doi.org/10.11604/pamj.2013.14.3.2181
   PubMedGoogle Scholar
• Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Del Rev 2005; 57:391-410; PMID:15560948; http://dx.doi.org/10.1016/j.addr.2004.09.003
   PubMed Web of Science ®Google Scholar
• Cleland JL. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol 1999; 17:25-9; PMID:10098275; http://dx.doi.org/10.1016/S0167-7799(98)01272-4
   PubMed Web of Science ®Google Scholar
• Aguado MT. Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. Vaccine 1993; 11:596-7; PMID:8488720; http://dx.doi.org/10.1016/0264-410X(93)90241-O
   PubMed Web of Science ®Google Scholar
• Coombes AG, Lavelle EC, Jenkins PG, Davis SS. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 1996; 14:1429-38; PMID:8994318; http://dx.doi.org/10.1016/S0264-410X(96)00077-1
   PubMed Web of Science ®Google Scholar
• Langer R, Cleland JL, Hanes J. New advances in microsphere-based single-dose vaccines. Adv Drug Del Rev 1997; 28:97-119; PMID:10837567; http://dx.doi.org/10.1016/S0169-409X(97)00053-7
   PubMed Web of Science ®Google Scholar
• Gupta RK, Singh M, O'Hagan DT. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Del Rev 1998; 32:225-46; PMID:10837646; http://dx.doi.org/10.1016/S0169-409X(98)00008-8
   PubMed Web of Science ®Google Scholar
• Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 1996; 85:1261-70; PMID:8961136; http://dx.doi.org/10.1021/js9602812
   PubMed Web of Science ®Google Scholar
• Singh M, Singh O, Singh A, Talwar GP. Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres. Int J Pharm 1992; 85:R5-R8; http://dx.doi.org/10.1016/0378-5173(92)90157-W
   Google Scholar
• Thomasin C, Corradin G, Men Y, Merkle HP, Gander B. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J Control Release 1996; 41:131-45; http://dx.doi.org/10.1016/0168-3659(96)01363-6
   Web of Science ®Google Scholar
• Lee HK, Park JH, Kwon KC. Double-walled microparticles for single shot vaccine. J Control Release 1997; 44:283-93; http://dx.doi.org/10.1016/S0168-3659(96)01534-9
   Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol 2012; 509:143-63.; PMID:22568905; http://dx.doi.org/10.1016/B978-0-12-391858-1.00008-3
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release: Off J Control Release Soc 2001; 70:1-20; PMID:11166403; http://dx.doi.org/10.1016/S0168-3659(00)00339-4
   PubMed Web of Science ®Google Scholar
• Kreutz M, Tacken PJ, Figdor CG. Targeting dendritic cells–why bother? Blood 2013; 121:2836-44; PMID:23390195; http://dx.doi.org/10.1182/blood-2012-09-452078
   PubMedGoogle Scholar
• Desai KG, Schwendeman SP. Active self-healing encapsulation of vaccine antigens in PLGA microspheres. J Control Release: Off J Control Release Soc 2013; 165:62-74; PMID:23103983; http://dx.doi.org/10.1016/j.jconrel.2012.10.012
   PubMed Web of Science ®Google Scholar
• Alonso MJ, Gupta RK, Min C, Siber GR, Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994; 12:299-306; PMID:8178550; http://dx.doi.org/10.1016/0264-410X(94)90092-2
   PubMed Web of Science ®Google Scholar
• Sanders LM, McRae GI, Vitale KM, Kell BA. Controlled delivery of an LHRH analogue from biodegradable injectable microspheres. J Control Release 1985; 2:187-95; http://dx.doi.org/10.1016/0168-3659(85)90044-6
   Google Scholar
• Cowsar DR, Tice TR, Gilley RM, English JP. Poly(lactide-co-glycolide) microcapsules for controlled release of steroids. Methods Enzymol 1985; 112:101-16; PMID:4046844; http://dx.doi.org/; http://dx.doi.org/10.1016/S0076-6879(85)12010-0
   PubMed Web of Science ®Google Scholar
• Singh M, Singh O, Talwar GP. Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys. Pharm Res 1995; 12:1796-800; PMID:8592689; http://dx.doi.org/10.1023/A:1016294512292
   PubMed Web of Science ®Google Scholar
• Johansen P, Estevez F, Zurbriggen R, Merkle HP, Gluck R, Corradin G, Gander B. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 2000; 19:1047-54; PMID:11137238; http://dx.doi.org/10.1016/S0264-410X(00)00343-1
   PubMed Web of Science ®Google Scholar
• Bloom BR. Vaccines for the Third World. Nature 1989; 342:115-20; PMID:2812009; http://dx.doi.org/10.1038/342115a0
   PubMedGoogle Scholar
• Aguado MT, Lambert PH. Controlled-release vaccines–biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology 1992; 184:113-25; PMID:1587538; http://dx.doi.org/10.1016/S0171-2985(11)80470-5
   PubMed Web of Science ®Google Scholar
• Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 1993; 10:945-53; PMID:8378256; http://dx.doi.org/10.1023/A:1018942118148
   PubMed Web of Science ®Google Scholar
• Sanchez A, Gupta RK, Alonso MJ, Siber GR, Langer R. Pulsed controlled-released system for potential use in vaccine delivery. J Pharm Sci 1996; 85:547-52; PMID:8773947; http://dx.doi.org/10.1021/js960069y
   PubMed Web of Science ®Google Scholar
• Men Y, Thomasin C, Merkle HP, Gander B, Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 1995; 13:683-9; PMID:7668038; http://dx.doi.org/10.1016/0264-410X(94)00046-P
   PubMed Web of Science ®Google Scholar
• Jung T, Koneberg R, Hungerer KD, Kissel T. Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice. Int J Pharm 2002; 234:75-90; PMID:11839439; http://dx.doi.org/10.1016/S0378-5173(01)00957-7
   PubMed Web of Science ®Google Scholar
• Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, O'Hagan DT. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 1997; 65:1716-21; PMID:9125552
   PubMed Web of Science ®Google Scholar
• Johansen P, Moon L, Tamber H, Merkle HP, Gander B, Sesardic D. Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 1999; 18:209-15; PMID:10506644; http://dx.doi.org/10.1016/S0264-410X(99)00191-7
   PubMed Web of Science ®Google Scholar
• Peyre M, Sesardic D, Merkle HP, Gander B, Johansen P. An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. J Pharm Sci 2003; 92:957-66; PMID:12712415; http://dx.doi.org/10.1002/jps.10361
   PubMed Web of Science ®Google Scholar
• Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol Bioeng 2012; 109:1443-60; PMID:22407777; http://dx.doi.org/10.1002/bit.24493
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995; 13:1006-12; PMID:8525683; http://dx.doi.org/10.1016/0264-410X(95)00016-T
   PubMed Web of Science ®Google Scholar
• Johansson EL, Wassen L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001; 69:7481-6; PMID:11705923; http://dx.doi.org/10.1128/IAI.69.12.7481-7486.2001
   PubMed Web of Science ®Google Scholar
• Rudin A, Riise GC, Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun 1999; 67:2884-90; PMID:10338495
   PubMed Web of Science ®Google Scholar
• Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997; 65:2676-84; PMID:9199436
   PubMed Web of Science ®Google Scholar
• Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169:566-74; PMID:12077289; http://dx.doi.org/10.4049/jimmunol.169.1.566
   PubMed Web of Science ®Google Scholar
• Liang B, Hyland L, Hou S. Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J Virol 2001; 75:5416-20; PMID:11333927; http://dx.doi.org/10.1128/JVI.75.11.5416-5420.2001
   PubMedGoogle Scholar
• Hanes J, Chiba M, Langer R. Polymer microspheres for vaccine delivery. Pharm Biotechnol 1995; 6:389-412; PMID:7551227; http://dx.doi.org/10.1007/978-1-4615-1823-5_16
   PubMedGoogle Scholar
• Eldridge JH, Meulbroek JA, Staas JK, Tice TR, Gilley RM. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 1989; 251:191-202; PMID:2610110
   PubMedGoogle Scholar
• Eyles JE, Sharp GJ, Williamson ED, Spiers ID, Alpar HO. Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 1998; 16:698-707; PMID:9562689; http://dx.doi.org/10.1016/S0264-410X(97)00249-1
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target 1996; 3:455-67; PMID:8863138; http://dx.doi.org/10.3109/10611869609015965
   PubMed Web of Science ®Google Scholar
• Beier R, Gebert A. Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol 1998; 275:G130-7; PMID:9655693
   PubMed Web of Science ®Google Scholar
• Yeh M-K, Liu Y-T, Chen J-L, Chiang C-H. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. J Control Release 2002; 82:237-47; PMID:12175740; http://dx.doi.org/10.1016/S0168-3659(02)00140-2
   PubMed Web of Science ®Google Scholar
• Yeh M, Chiang C. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. J Microencapsul 2004; 21:91-106; PMID:14718189; http://dx.doi.org/10.1080/02652040310001619794
   PubMed Web of Science ®Google Scholar
• Huang SS, Li IH, Hong PD, Yeh MK. Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague. Int J Nanomed 2014; 9:813-22; PMID:24550673
   PubMed Web of Science ®Google Scholar
• Huang SS, Li IH, Hong PD, Yeh MK. Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus. Int J Nanomed 2013; 8:3161-9; PMID:23990724
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis: Off Pub Infect Dis Soc Am 2008; 47:401-9; PMID:18558875; http://dx.doi.org/10.1086/589862
   PubMed Web of Science ®Google Scholar
• Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-10; PMID:15286782; http://dx.doi.org/10.1038/nm0804-806]
   PubMed Web of Science ®Google Scholar
• Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372:164-75; PMID:18620952; http://dx.doi.org/10.1016/S0140-6736(08)61036-3
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Pearson FE, Todryk S, Ewer K. Potency assays for novel T-cell-inducing vaccines against malaria. Curr Opin Mol Therap 2009; 11:72-80; PMID:19169962
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008; 29:319-24; PMID:18799140; http://dx.doi.org/10.1016/j.immuni.2008.08.001
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:15122249; http://dx.doi.org/10.1038/nm1039
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Cheong C, Suda K, Suda N, Kim JY, Lee H, Park CG, Steinman RM. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol 2008; 180:3647-50; PMID:18322168; http://dx.doi.org/10.4049/jimmunol.180.6.3647
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, Mucida D, Merad M, Steinman RM. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844-54; PMID:23298832
   PubMed Web of Science ®Google Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:1249-55; PMID:10545990; http://dx.doi.org/10.1038/15200
   PubMed Web of Science ®Google Scholar
• Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines - hope or hype? Nat Rev Immunol 2014; 14:705-11; PMID:25190285; http://dx.doi.org/10.1038/nri3727
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release: Off J Control Release Soc 2010; 144:118-26; PMID:20156497; http://dx.doi.org/10.1016/j.jconrel.2010.02.013
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold B, Keskin DB, Reinherz EL, Sasada T. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011; 32:3666-78; PMID:21345488; http://dx.doi.org/10.1016/j.biomaterials.2011.01.067
   PubMed Web of Science ®Google Scholar
• Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008; 26:1626-37; PMID:18295941; http://dx.doi.org/10.1016/j.vaccine.2008.01.030
   PubMed Web of Science ®Google Scholar
• Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005; 26:5727-36; PMID:15878378; http://dx.doi.org/10.1016/j.biomaterials.2005.02.025
   PubMed Web of Science ®Google Scholar
• Duncanson WJ, Figa MA, Hallock K, Zalipsky S, Hamilton JA, Wong JY. Targeted binding of PLA microparticles with lipid-PEG-tethered ligands. Biomaterials 2007; 28:4991-9; PMID:17707503; http://dx.doi.org/10.1016/j.biomaterials.2007.05.044
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 2011; 32:6791-803; PMID:21724247; http://dx.doi.org/10.1016/j.biomaterials.2011.04.082
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 2012; 14:17-46; PMID:22524387; http://dx.doi.org/10.1146/annurev-bioeng-071811-150054
   PubMed Web of Science ®Google Scholar
• Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013; 3:13; PMID:23532930; http://dx.doi.org/10.3389/fcimb.2013.00013
   PubMed Web of Science ®Google Scholar
• Fu PP. Introduction to the special issue: nanomaterials– toxicology and medical applications. J Food Drug Anal 2014; 22:1-2; PMID:24673899; http://dx.doi.org/10.1016/j.jfda.2014.01.013
   PubMedGoogle Scholar
• Karmakar A, Zhang Q, Zhang Y. Neurotoxicity of nanoscale materials. J Food Drug Anal 2014; 22:147-60; PMID:24673911; http://dx.doi.org/10.1016/j.jfda.2014.01.012
   PubMed Web of Science ®Google Scholar
• McShan D, Ray PC, Yu H. Molecular toxicity mechanism of nanosilver. J Food Drug Anal 2014; 22:116-27; PMID:24673909; http://dx.doi.org/10.1016/j.jfda.2014.01.010
   PubMed Web of Science ®Google Scholar
• Guo X, Mei N. Assessment of the toxic potential of graphene family nanomaterials. J Food Drug Anal 2014; 22:105-15; PMID:24673908; http://dx.doi.org/10.1016/j.jfda.2014.01.009
   PubMed Web of Science ®Google Scholar
• Chen T, Yan J, Li Y. Genotoxicity of titanium dioxide nanoparticles. J Food Drug Anal 2014; 22:95-104; PMID:24673907; http://dx.doi.org/10.1016/j.jfda.2014.01.008
   PubMed Web of Science ®Google Scholar
• Wu H, Yin JJ, Wamer WG, Zeng M, Lo YM. Reactive oxygen species-related activities of nano-iron metal and nano-iron oxides. J Food Drug Anal 2014; 22:86-94; PMID:24673906; http://dx.doi.org/10.1016/j.jfda.2014.01.007
   PubMed Web of Science ®Google Scholar
• Li M, Yin JJ, Wamer WG, Lo YM. Mechanistic characterization of titanium dioxide nanoparticle-induced toxicity using electron spin resonance. J Food Drug Anal 2014; 22:76-85; PMID:24673905; http://dx.doi.org/10.1016/j.jfda.2014.01.006
   PubMedGoogle Scholar
• Fu PP, Xia Q, Hwang HM, Ray PC, Yu H. Mechanisms of nanotoxicity: generation of reactive oxygen species. J Food Drug Anal 2014; 22:64-75; PMID:24673904; http://dx.doi.org/10.1016/j.jfda.2014.01.005
   PubMed Web of Science ®Google Scholar
• Serda RE. Particle platforms for cancer immunotherapy. Int J Nanomed 2013; 8:1683-96; PMID:23761969; http://dx.doi.org/10.2147/IJN.S31756
   PubMed Web of Science ®Google Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007; 96:203-9; PMID:17191251; http://dx.doi.org/10.1002/bit.21301
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IF, Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004; 173:3148-54; PMID:15322175; http://dx.doi.org/10.4049/jimmunol.173.5.3148
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38:1404-13; PMID:18389478; http://dx.doi.org/10.1002/eji.200737984
   PubMed Web of Science ®Google Scholar
• Slutter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010; 28:6282-91; PMID:20638455; http://dx.doi.org/10.1016/j.vaccine.2010.06.121
   PubMed Web of Science ®Google Scholar
• Baca-Estrada ME, Foldvari M, Snider M. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interf Cytok Res: Off J Int Soc Interf Cytok Res 1999; 19:455-62; PMID:10386857; http://dx.doi.org/10.1089/107999099313893
   PubMed Web of Science ®Google Scholar